Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.

Journal Article (Journal Article)

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease.

Full Text

Duke Authors

Cited Authors

  • Mohler, JL; Armstrong, AJ; Bahnson, RR; Boston, B; Busby, JE; D'Amico, AV; Eastham, JA; Enke, CA; Farrington, T; Higano, CS; Horwitz, EM; Kantoff, PW; Kawachi, MH; Kuettel, M; Lee, RJ; MacVicar, GR; Malcolm, AW; Miller, D; Plimack, ER; Pow-Sang, JM; Roach, M; Rohren, E; Rosenfeld, S; Srinivas, S; Strope, SA; Tward, J; Twardowski, P; Walsh, PC; Ho, M; Shead, DA

Published Date

  • September 2012

Published In

Volume / Issue

  • 10 / 9

Start / End Page

  • 1081 - 1087

PubMed ID

  • 22956807

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2012.0114


  • eng

Conference Location

  • United States